The unfold of coronavirus illness 2019 (COVID-19) all through the world has resulted in anxious healthcare burdens and international well being crises. Creating an efficient measure to guard individuals from an infection is an pressing want. The blockage of interplay between angiotensin-converting enzyme 2 (ACE2) and S protein is taken into account an important goal for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) medication.
A full-length ACE2 protein may very well be a possible drug to dam early entry of SARS-CoV-2 into host cells. On this examine, a therapeutic technique was developed through the use of extracellular vesicles (EVs) with decoy receptor ACE2 for neutralization of SARS-CoV-2.
The EVs embedded with engineered ACE2 (EVs-ACE2) had been ready; the EVs-ACE2 had been derived from an engineered cell line with steady ACE2 expression. The potential impact of the EVs-ACE2 on anti-SARS-CoV-2 was demonstrated by each in vitro and in vivo neutralization experiments utilizing the pseudovirus with the S protein (S-pseudovirus).
EVs-ACE2 can inhibit the an infection of S-pseudovirus in varied cells, and importantly, the mice handled with intranasal administration of EVs-ACE2 can suppress the entry of S-pseudovirus into the mucosal epithelium. Due to this fact, the intranasal EVs-ACE2 may very well be a preventive medication to guard from SARS-CoV-2 an infection. This EVs-based technique provides a possible path to COVID-19 drug growth.
Results of endurance coaching on the expression of host proteins concerned in SARS-CoV-2 cell entry in C57BL/6J mouse
The coronavirus illness 2019 (COVID-19) pandemic, brought on by extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is threatening individuals’s lives and impacting their well being. It’s nonetheless unclear whether or not individuals engaged in bodily exercise are at an elevated threat of SARS-CoV-2 an infection and extreme types of COVID-19. To be able to present knowledge to assist reply this query, we, subsequently, investigated the consequences of endurance coaching on the degrees of host proteins concerned in SARS-CoV-2 an infection in mice.
Eight-week-old C57BL/6J mice had been subjected to treadmill operating (17-25 m/min, 60-90 min, 5 classes/week, Eight weeks). After the intervention, the degrees of angiotensin-converting enzyme 2 (ACE2; host receptor for SARS-CoV-2), transmembrane protease serine 2 (TMPRSS2; host protease priming fusion of SARS-CoV-2 to host cell membranes), FURIN (host protease that promotes binding of SARS-CoV-2 to host receptors), and Neuropilin-1 (host coreceptor for SARS-CoV-2) had been measured in 10 organs that SARS-CoV-2 can infect (larynx, trachea, lung, coronary heart, jejunum, ileum, colon, liver, kidney, and testis).
Six organs (coronary heart, lung, jejunum, liver, trachea, and ileum) confirmed adjustments within the ranges of at the very least one of many proteins. Endurance coaching elevated ACE2 ranges in coronary heart (+66.4%), lung (+37.1%), jejunum (+24.7%) and liver (+27.4%), and FURIN in liver (+17.9%) tissue. In distinction, endurance coaching decreased Neuropilin-1 ranges in liver (-39.7%), trachea (-41.2%), and ileum (-39.7%), and TMPRSS2 in lung (-11.3%). Taken collectively, endurance coaching altered the degrees of host proteins concerned in SARS-CoV-2 cell entry in an organ-dependent method.
Histopathological options of SARS-CoV-2 an infection and relationships with organoid expertise
Coronavirus illness 2019 (COVID-19) following an infection by extreme acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has precipitated a world pandemic that’s nonetheless having critical results worldwide. This virus, which targets the lungs particularly, may injury different tissues. Angiotensin changing enzyme 2 (ACE-2) performs a key position in viral entry into host cells.
The presence of ACE-2 in varied tissues might allow viral an infection. Research of COVID-19 usually make use of postmortem tissues. Though this data supplies varied helpful outcomes, it is usually essential to conduct in vitro research to grasp optimum remedy approaches. As a result of the virus might present species-specific variations, in vitro applied sciences utilizing human cells are notably necessary.
Organoid applied sciences, three-dimensional constructions that may be obtained from human cells, are taking part in more and more necessary roles in research of SARS-CoV-2. This expertise provides a big benefit by way of mimicking in vivo tissue constructions and testing antiviral compounds. On this mini-review, we summarize research of SARS-CoV-2 utilizing each histopathological and organoid expertise approaches.
Serological evaluation of SARS-CoV-2 an infection in the course of the first wave of the pandemic in Louisville Kentucky
Serological assays meant for analysis, sero-epidemiologic evaluation, and measurement of protecting antibody titers upon an infection or vaccination are important for managing the SARS-CoV-2 pandemic. Serological assays measuring the antibody responses in opposition to SARS-CoV-2 antigens are available. Nonetheless, some lack acceptable traits to precisely measure SARS-CoV-2 antibodies titers and neutralization.
We developed an Enzyme-linked Immunosorbent Assay (ELISA) strategies for measuring IgG, IgA, and IgM responses to SARS-CoV-2, Spike (S), receptor binding area (RBD), and nucleocapsid (N) proteins. Efficiency traits of sensitivity and specificity have been outlined. ELISA outcomes present optimistic correlation with microneutralization and Plaque Discount Neutralization assays with infectious SARS-CoV-2.
Our ELISA was used to display screen healthcare employees in Louisville, KY in the course of the first wave of the native pandemic within the months of Could and July 2020. We discovered a seropositive charge of roughly 1.4% and a couple of.3%, respectively. Our analyses reveal a broad immune response amongst people and counsel some non-RBD particular S IgG and IgA antibodies neutralize SARS-CoV-2.
Cardiovascular tissue banking exercise throughout SARS-CoV-2 pandemic: evolution of nationwide protocols and Lombardy expertise
The worldwide pandemic outbreak attributable to extreme acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has created unprecedented challenges for public well being companies. Lombardy, area of the Northern Italy, has been the primary space within the Western world whose organs and tissues procurement applications have needed to face the virus pandemic emergency.
We retrospectively collected and analyzed knowledge about cardiovascular tissues (CT) in 2019 and in 2020. We aimed to explain the speedy evolution of SARS-CoV-2 regulation legal guidelines for tissue donor’s choice and harvesting from February 2020 till January 2021. As anticipated the variety of CT donors in 2020 was considerably decrease than these of 2019 (66 vs. 99, p worth 0.02).
The entire variety of CT collected from donors have been 254 in 2019 and 206 in 2020 (p 0.28). Femoral arteries had been essentially the most required vascular tissues (55.5% in 2019 and 40% in 2020). Fifty-five and forty-eight pulmonary valves had been implanted in 2019 and 2020, respectively.
Seryl-tRNA Synthetase 2, Mitochondrial (SARS2) Antibody |
abx033708-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Seryl-tRNA Synthetase 2, Mitochondrial (SARS2) Antibody |
abx033708-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Seryl-tRNA Synthetase 2, Mitochondrial (SARS2) Antibody |
20-abx126510 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Seryl-tRNA Synthetase 2, Mitochondrial (SARS2) Antibody |
20-abx003637 |
Abbexa |
|
|
|
SARS2 siRNA |
20-abx932471 |
Abbexa |
|
|
|
SARS2 siRNA |
20-abx932472 |
Abbexa |
|
|
|
SARS2 Rabbit pAb |
A12297-100ul |
Abclonal |
100 ul |
EUR 369.6 |
SARS2 Rabbit pAb |
A12297-200ul |
Abclonal |
200 ul |
EUR 550.8 |
SARS2 Rabbit pAb |
A12297-20ul |
Abclonal |
20 ul |
EUR 219.6 |
SARS2 Rabbit pAb |
A12297-50ul |
Abclonal |
50 ul |
EUR 267.6 |
SARS2 cloning plasmid |
CSB-CL878836HU-10ug |
Cusabio |
10ug |
EUR 451.2 |
|
Description: A cloning plasmid for the SARS2 gene. |
Mouse SARS2 shRNA Plasmid |
20-abx977615 |
Abbexa |
|
|
|
Human SARS2 shRNA Plasmid |
20-abx960340 |
Abbexa |
|
|
|
SARS2 Recombinant Protein (Rat) |
RP227483 |
ABM |
100 ug |
Ask for price |
SARS2 Recombinant Protein (Mouse) |
RP170015 |
ABM |
100 ug |
Ask for price |
SARS2 Recombinant Protein (Human) |
RP027610 |
ABM |
100 ug |
Ask for price |
Sars2 ORF Vector (Rat) (pORF) |
ORF075829 |
ABM |
1.0 ug DNA |
EUR 607.2 |
SARS2 ORF Vector (Human) (pORF) |
ORF009204 |
ABM |
1.0 ug DNA |
EUR 114 |
Sars2 ORF Vector (Mouse) (pORF) |
ORF056673 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Sars2 sgRNA CRISPR Lentivector set (Rat) |
K6129701 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Sars2 sgRNA CRISPR Lentivector set (Mouse) |
K3850001 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
SARS2 sgRNA CRISPR Lentivector set (Human) |
K2089901 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Sars2 3'UTR GFP Stable Cell Line |
TU168351 |
ABM |
1.0 ml |
Ask for price |
SARS2 3'UTR GFP Stable Cell Line |
TU072597 |
ABM |
1.0 ml |
EUR 1672.8 |
Sars2 3'UTR GFP Stable Cell Line |
TU269921 |
ABM |
1.0 ml |
Ask for price |
SARS2 Protein Vector (Rat) (pPM-C-HA) |
PV303316 |
ABM |
500 ng |
EUR 723.6 |
SARS2 Protein Vector (Rat) (pPB-C-His) |
PV303314 |
ABM |
500 ng |
EUR 723.6 |
SARS2 Protein Vector (Rat) (pPB-N-His) |
PV303315 |
ABM |
500 ng |
EUR 723.6 |
SARS2 Protein Vector (Rat) (pPM-C-His) |
PV303317 |
ABM |
500 ng |
EUR 723.6 |
SARS2 Protein Vector (Human) (pPM-C-HA) |
PV036815 |
ABM |
500 ng |
EUR 394.8 |
SARS2 Protein Vector (Mouse) (pPM-C-HA) |
PV226692 |
ABM |
500 ng |
EUR 723.6 |
SARS2 Protein Vector (Human) (pPB-C-His) |
PV036813 |
ABM |
500 ng |
EUR 394.8 |
SARS2 Protein Vector (Human) (pPB-N-His) |
PV036814 |
ABM |
500 ng |
EUR 394.8 |
SARS2 Protein Vector (Human) (pPM-C-His) |
PV036816 |
ABM |
500 ng |
EUR 394.8 |
SARS2 Protein Vector (Mouse) (pPB-C-His) |
PV226690 |
ABM |
500 ng |
EUR 723.6 |
SARS2 Protein Vector (Mouse) (pPB-N-His) |
PV226691 |
ABM |
500 ng |
EUR 723.6 |
SARS2 Protein Vector (Mouse) (pPM-C-His) |
PV226693 |
ABM |
500 ng |
EUR 723.6 |
Sars2 3'UTR Luciferase Stable Cell Line |
TU118351 |
ABM |
1.0 ml |
Ask for price |
SARS2 3'UTR Luciferase Stable Cell Line |
TU022597 |
ABM |
1.0 ml |
EUR 1672.8 |
Sars2 3'UTR Luciferase Stable Cell Line |
TU219921 |
ABM |
1.0 ml |
Ask for price |
Sars2 sgRNA CRISPR Lentivector (Rat) (Target 1) |
K6129702 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Sars2 sgRNA CRISPR Lentivector (Rat) (Target 2) |
K6129703 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Sars2 sgRNA CRISPR Lentivector (Rat) (Target 3) |
K6129704 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Sars2 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K3850002 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Sars2 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K3850003 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Sars2 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K3850004 |
ABM |
1.0 ug DNA |
EUR 184.8 |
SARS2 sgRNA CRISPR Lentivector (Human) (Target 1) |
K2089902 |
ABM |
1.0 ug DNA |
EUR 184.8 |
SARS2 sgRNA CRISPR Lentivector (Human) (Target 2) |
K2089903 |
ABM |
1.0 ug DNA |
EUR 184.8 |
SARS2 sgRNA CRISPR Lentivector (Human) (Target 3) |
K2089904 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Mouse Seryl- tRNA synthetase, mitochondrial, Sars2 ELISA KIT |
ELI-41698m |
Lifescience Market |
96 Tests |
EUR 1038 |
Human Seryl- tRNA synthetase, mitochondrial, SARS2 ELISA KIT |
ELI-18558h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Bovine Seryl- tRNA synthetase, mitochondrial, SARS2 ELISA KIT |
ELI-52192b |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Human Seryl-tRNA Synthetase 2, Mitochondrial (SARS2) ELISA Kit |
abx383028-96tests |
Abbexa |
96 tests |
EUR 1093.2 |
|
Sars2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
K6129705 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Sars2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
K3850005 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
SARS2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
K2089905 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Sars2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
K6129706 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Sars2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
K6129707 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Sars2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
K6129708 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Sars2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K3850006 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Sars2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
K3850007 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Sars2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
K3850008 |
ABM |
1.0 ug DNA |
EUR 200.4 |
SARS2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
K2089906 |
ABM |
1.0 ug DNA |
EUR 200.4 |
SARS2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
K2089907 |
ABM |
1.0 ug DNA |
EUR 200.4 |
SARS2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
K2089908 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Anti-SARS2 antibody |
STJ114185 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes the mitochondrial seryl-tRNA synthethase precursor, a member of the class II tRNA synthetase family. The mature enzyme catalyzes the ligation of Serine to tRNA(Ser) and participates in the biosynthesis of selenocysteinyl-tRNA(sec) in mitochondria. The enzyme contains an N-terminal tRNA binding domain and a core catalytic domain. It functions in a homodimeric form, which is stabilized by tRNA binding. This gene is regulated by a bidirectional promoter that also controls the expression of mitochondrial ribosomal protein S12. Both genes are within the critical interval for the autosomal dominant deafness locus DFNA4 and might be linked to this disease. Multiple transcript variants encoding different isoforms have been identified for this gene. |
SARS antibody |
39139-100ul |
SAB |
100ul |
EUR 302.4 |
SARS antibody |
70R-1444 |
Fitzgerald |
100 ug |
EUR 452.4 |
Description: Rabbit polyclonal SARS antibody raised against the C terminal of SARS |
SARS antibody |
70R-1445 |
Fitzgerald |
100 ug |
EUR 452.4 |
Description: Rabbit polyclonal SARS antibody raised against the middle region of SARS |
SARS antibody |
70R-20086 |
Fitzgerald |
50 ul |
EUR 522 |
Description: Rabbit polyclonal SARS antibody |
SARS Antibody |
1-CSB-PA04145A0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
SARS Antibody |
1-CSB-PA020709GA01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
SARS E2 antibody |
10R-1976 |
Fitzgerald |
100 ul |
EUR 289.2 |
Description: Mouse monoclonal SARS E2 antibody |
SARS M antibody |
10R-1977 |
Fitzgerald |
100 ul |
EUR 289.2 |
Description: Mouse monoclonal SARS M antibody |
SARS1 Antibody / Seryl-tRNA synthetase / SERS |
RQ7414 |
NSJ Bioreagents |
100ug |
EUR 419 |
anti- SARS antibody |
FNab07609 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against SARS |
SARS Antibody, HRP conjugated |
1-CSB-PA04145B0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
SARS-M Antibody |
abx016056-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
SARS Antibody, FITC conjugated |
1-CSB-PA04145C0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
SARS-E2 Antibody |
abx016055-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
SARS Antibody, Biotin conjugated |
1-CSB-PA04145D0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
SARS Spike Antibody |
20-abx137184 |
Abbexa |
-
EUR 1262.40
-
EUR 1846.80
-
EUR 2064.00
|
|
|
SARS Spike Antibody |
20-abx137200 |
Abbexa |
-
EUR 1412.40
-
EUR 2264.40
-
EUR 2665.20
|
|
|
SARS Spike Antibody |
24216-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24217-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24218-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24219-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24318-100ul |
SAB |
100ul |
EUR 468 |
SARS Matrix Antibody |
24319-100ul |
SAB |
100ul |
EUR 468 |
SARS Matrix Antibody |
24320-100ul |
SAB |
100ul |
EUR 468 |
SARS virus Sn Antibody |
abx032683-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
SARS virus Sn Antibody |
abx032683-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
SARS virus Sm Antibody |
abx032684-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
SARS virus Sm Antibody |
abx032684-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
SARS Envelope Antibody |
24321-100ul |
SAB |
100ul |
EUR 468 |
SARS Envelope Antibody |
24322-100ul |
SAB |
100ul |
EUR 468 |
SARS N Protein Antibody |
abx018255-100ug |
Abbexa |
100 ug |
EUR 460.8 |
|
SARS N Protein Antibody |
abx018256-100ug |
Abbexa |
100 ug |
EUR 460.8 |
|
PLPro Antibody (SARS-CoV) |
100863 |
BPS Bioscience |
250 µg |
EUR 360 |
Description: Chicken polyclonal antibody recognizing the SARS-CoV Papain-like Protease (PLpro) as a 35 kDa protein. Purified from egg yolks. This antibody recognizes PLPro from both SARS-CoV-1 and SARS-CoV-2. Does not cross react with SARS-CoV 3CL protease. |
SARS-CoV Spike Antibody |
3219-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS Conjugated Antibody |
C39139 |
SAB |
100ul |
EUR 476.4 |
SARS Polyclonal Antibody |
A53977 |
EpiGentek |
-
EUR 684.66
-
EUR 117.70
-
EUR 302.50
-
EUR 423.50
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
SARS-CoV Matrix Antibody |
3527-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
3527-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
3529-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
3529-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV-2 Antibody (ORF8) |
RQ6296 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF8 encodes a viral accessory protein. |
SARS-CoV-2 Antibody (NSP2) |
RQ6299 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP3) |
RQ6300 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined. ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP4) |
RQ6301 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP7) |
RQ6302 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP8) |
RQ6303 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP9) |
RQ6304 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS Coronavirus antibody |
10C-CR9003M1 |
Fitzgerald |
100 ug |
EUR 598.8 |
Description: Mouse monoclonal SARS Coronavirus antibody |
ACE2 (SARS Receptor) Antibody |
abx032686-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
ACE2 (SARS Receptor) Antibody |
abx032686-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
SARS-CoV-2 Antibody (ORF3a) |
RQ6295 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined. ORF3a encodes a viral accessory protein. Based on its similarity to other coronavirus proteins, ORF3a protein is thought to be a protein with ion channel activity (viroporin) that activates the NLRP3 inflammasome. ORF3a may also play a role in virus replication and pathogenesis. |
SARS-CoV-2 Antibody (NSP10) |
RQ6305 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS Nucleocapsid Antibody |
20-abx137185 |
Abbexa |
-
EUR 1262.40
-
EUR 1846.80
-
EUR 2364.00
|
|
|
SARS Nucleocapsid Antibody |
20-abx137201 |
Abbexa |
-
EUR 1412.40
-
EUR 2264.40
-
EUR 2665.20
|
|
|
SARS Nucleocapsid antibody |
10R-10470 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
SARS Nucleocapsid antibody |
10R-10471 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
SARS-CoV Envelope Antibody |
3533-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS-CoV Envelope Antibody |
3533-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
Polyclonal SARS Matrix Antibody |
APR11178G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications: |
Polyclonal SARS Matrix Antibody |
APG02976G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications: |
SARS-CoV spike protein Antibody |
abx023139-100ug |
Abbexa |
100 ug |
EUR 1028.4 |
|
SARS-CoV spike protein Antibody |
abx023143-100ug |
Abbexa |
100 ug |
EUR 1028.4 |
|
Seryl-tRNA Synthetase, Cytoplasmic (SARS) Antibody |
abx237609-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
Seryl-tRNA Synthetase, Cytoplasmic (SARS) Antibody |
20-abx110210 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Seryl-tRNA Synthetase, Cytoplasmic (SARS) Antibody |
20-abx115486 |
Abbexa |
|
|
|
Seryl-tRNA Synthetase, Cytoplasmic (SARS) Antibody |
20-abx005165 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Anti-Spike S1 Antibody (SARS-CoV-2) |
100715-1 |
BPS Bioscience |
20 µg |
EUR 300 |
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. |
Anti-Spike S1 Antibody (SARS-CoV-2) |
100715-2 |
BPS Bioscience |
100 µg |
EUR 440 |
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
9155-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
9155-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
9159-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
9159-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
9161-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
9161-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
9163-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
9163-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
9167-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
9167-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP2 Antibody |
9171-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP2 may play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses (3). |
SARS-CoV-2 (COVID-19) NSP2 Antibody |
9171-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP2 may play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses (3). |
SARS-CoV-2 (COVID-19) NSP2 Antibody |
9173-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP2 may play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses (3). |
SARS-CoV-2 (COVID-19) NSP2 Antibody |
9173-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP2 may play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses (3). |
No variations had been discovered for the forms of CT requests between the two years. The median age of receivers of vascular tissues was 69.6 ± 14.6 years within the 2019 and 63.3 ± 14.9 years in 2020 (p < 0.01). The median age of receivers of pulmonary and aortic valves didn’t differ between the two years (9.32 ± 11.49 vs. 8.36 ± 10.66 and 48.67 ± 27.19 vs. 37.14 ± 31.97 respectively). Regardless of the dramatically discount of donors, the variety of CT collected has not decreased considerably and to this point the CT distribution charge is corresponding to these of 2019.